The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the familial amyloidotic polyneuropathy world transplant registry
Abstract
BACKGROUND: Transthyretin (TTR) amyloidosis is a group of systemic amyloidoses disorders caused by an amyloidogenic TTR variant. Untreated, it slowly leads to severely disabling symptoms that relentlessly progress until the death of the patient. Because the mutant form of TTR is produced mainly in the liver, successful orthotopic liver transplantation (OLT) results in the elimination of the source of the variant TTR molecule and is presently the only known curative treatment. OLT in patients with familial amyloidotic polyneuropathy (FAP) was first performed in 1990 at the Karolinska Institute in Sweden, and because the results were promising other centers took up the procedure. METHODS: To gain as great an experience as possible regarding this treatment, the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR) was initiated in 1995, and this article presents the 10-year registry results. RESULTS: A total of 54 centers in 16 countries have performed OLT for FAP, and today approximately 60 OLTs are performed annually worldwide. During the last decade, a total of 539 patients have undergone 579 OLTs. Patient survival is excellent (overall 5-year patient survival 77%) and comparable to the survival with OLT performed for other chronic liver disorders, but longer follow-up is needed to compare the outcome after OLT with the natural course of the disease. The main cause of death was cardiac related (39%). CONCLUSIONS: We believe that the FAPWTR has become a valuable tool that will help to accurately evaluate the potential risks and benefits of OLT in patients with FAP and promote a fruitful collaboration between centers engaged in this field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ANDRADE, C. (1952) · Brain · doi:10.1093/brain/75.3.408 · Cited by 1,074
Holmgren, G., Steen, L., Suhr, O., Ericzon, B.-G., Groth, C.-G., Andersen, O., Wallin, B. G., Seymour, A., Richardson, S., Hawkins, P. N., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)93127-m · Cited by 579
Self-citationAmyloid Deposits and Amyloidosis: The β-Fibrilloses(Second of Two Parts)
Glenner, G. G. (1980) · New England Journal of Medicine · doi:10.1056/nejm198006123022403 · Cited by 517
Holmgren, G., Steen, L., Ekstedt, J., Groth, C., Ericzon, B. ‐., Eriksson, S., Andersen, O., Karlberg, I., Nordén, G., Nakazato, M., et al. (1991) · Clinical Genetics · doi:10.1111/j.1399-0004.1991.tb03085.x · Cited by 396
Self-citationSUHR, O., DANIELSSON, Å., HOLMGREN, G., & STEEN, L. (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb01106.x · Cited by 209
Benson, M. D., & Uemichi, T. (1996) · Amyloid · doi:10.3109/13506129609014354 · Cited by 187
Yazaki, M., Tokuda, T., Nakamura, A., Higashikata, T., Koyama, J., Higuchi, K., Harihara, Y., Baba, S., Kametani, F., & Ikeda, S.-I. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3203 · Cited by 168
SUHR, O. B., HOLMGREN, G., STEEN, L., WIKSTRÖM, L., NORDEN, G., FRIMAN, S., DURAJ, F. F., GROTH, C. G., & ERICZON, B.-G. (1995) · Transplantation · doi:10.1097/00007890-199511000-00009 · Cited by 167
Self-citationFamilial Amyloid Polyneuropathy
Reilly, M. M., & King, R. H. M. (1993) · Brain Pathology · doi:10.1111/j.1750-3639.1993.tb00741.x · Cited by 46
Cited by
EASL Clinical Practice Guidelines: Liver transplantation
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.006 · Cited by 1,082
Martin, P., DiMartini, A., Feng, S., Brown, R., & Fallon, M. (2014) · Hepatology · doi:10.1002/hep.26972 · Cited by 1,045
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Guideline of transthyretin-related hereditary amyloidosis for clinicians
Ando, Y., Coelho, T., Berk, J. L., Cruz, M. W., Ericzon, B.-G., Ikeda, S.-I., Lewis, W. D., Obici, L., Planté-Bordeneuve, V., Rapezzi, C., et al. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-31 · Cited by 719
Self-citationTransthyretin (TTR) Cardiac Amyloidosis
Ruberg, F. L., & Berk, J. L. (2012) · Circulation · doi:10.1161/circulationaha.111.078915 · Cited by 708
Familial amyloid polyneuropathy
Planté-Bordeneuve, V., & Said, G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70246-0 · Cited by 645
Pepys, M. B. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131243 · Cited by 559
The molecular biology and clinical features of amyloid neuropathy
Benson, M. D., & Kincaid, J. C. (2007) · Muscle & Nerve · doi:10.1002/mus.20821 · Cited by 447
Targeting protein aggregation for the treatment of degenerative diseases
Eisele, Y. S., Monteiro, C., Fearns, C., Encalada, S. E., Wiseman, R. L., Powers, E. T., & Kelly, J. W. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4593 · Cited by 419
Transthyretin-related amyloidoses and the heart: a clinical overview
Rapezzi, C., Quarta, C. C., Riva, L., Longhi, S., Gallelli, I., Lorenzini, M., Ciliberti, P., Biagini, E., Salvi, F., & Branzi, A. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.67 · Cited by 350
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
Coelho, T., Maia, L. F., da Silva, A. M., Cruz, M. W., Planté-Bordeneuve, V., Suhr, O. B., Conceiçao, I., Schmidt, H. H.-J., Trigo, P., Kelly, J. W., et al. (2013) · Journal of Neurology · doi:10.1007/s00415-013-7051-7 · Cited by 344
Rapezzi, C., Quarta, C. C., Obici, L., Perfetto, F., Longhi, S., Salvi, F., Biagini, E., Lorenzini, M., Grigioni, F., Leone, O., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs123 · Cited by 332
Sekijima, Y. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308724 · Cited by 332
Rapezzi, C., Quarta, C. C., Guidalotti, P. L., Pettinato, C., Fanti, S., Leone, O., Ferlini, A., Longhi, S., Lorenzini, M., Reggiani, L. B., et al. (2011) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2011.03.016 · Cited by 331
Johnson, S. M., Connelly, S., Fearns, C., Powers, E. T., & Kelly, J. W. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.060 · Cited by 328
Report of the Paris Consensus Meeting on Expanded Criteria Donors in Liver Transplantation
Durand, F., Renz, J. F., Alkofer, B., Burra, P., Clavien, P.-A., Porte, R. J., Freeman, R. B., & Belghiti, J. (2008) · Liver Transplantation · doi:10.1002/lt.21668 · Cited by 304
Clinical aspects of systemic amyloid diseases
Obici, L., Perfetti, V., Palladini, G., Moratti, R., & Merlini, G. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.08.014 · Cited by 278
Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis
Kristen, A. V., Ajroud-Driss, S., Conceição, I., Gorevic, P., Kyriakides, T., & Obici, L. (2019) · Neurodegenerative Disease Management · doi:10.2217/nmt-2018-0033 · Cited by 268
Kristen, A. V., Dengler, T. J., Hegenbart, U., Schonland, S. O., Goldschmidt, H., Sack, F.-U., Voss, F., Becker, R., Katus, H. A., & Bauer, A. (2008) · Heart Rhythm · doi:10.1016/j.hrthm.2007.10.016 · Cited by 254
Metadata
- Authors
- Herlenius, G., Wilczek, H. E., Larsson, M., & Ericzon, B.-G.
- Venue
- Transplantation
- Published
- 2004-01-15
- Volume
- 77
- Issue
- 1
- Pages
- 64-71
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2064278776
- Cited by
- 275
- References
- 9
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.